Upload
philip-vaidyan
View
413
Download
2
Embed Size (px)
Citation preview
1
SODIUM–GLUCOSE CO-TRANSPORTERS (SGLTS) INHIBITORS
7/13/2015
2
INTRODUCTION
• T2DM progressive β-cell dysfunction & peripheral insulin resistance
• Persisting hyperglycemia β-cell dysfunction & worsens insulin resistance
• T2DM obese, HTN and dyslipidemia
• Need arises for new, well tolerated in all stages of disease
7/13/2015
3
MOA OF OHAS
7/13/2015
4
HISTORY
• Phlorizin, a bitter white glycoside isolated from apple tree bark by French chemists in 1835, is a naturally occurring inhibitor of both SGLT1 and SGLT2 and was used for the treatment of diabetes in the pre-insulin era.
7/13/2015
5
Familial Renal Glycosuria
• A rare inherited condition caused by a mutation in the SGLT2 gene.
• Patients with this condition have varying degrees of glycosuria
• They remain asymptomatic • They do not become dehydrated or become
hypoglycemic • They can excrete up to 125 g of glucose/day.
7/13/2015
6
SGLT2-INHIBITORS
• Sodium–glucose co-transporters (SGLTs) are the newest drugs
• MOA is by blocking the glucose reabsorption in the kidney, inhibitors of the sodium-glucose cotransporter 2 (SGLT2) increase the urinary glucose excretion
7/13/2015
77/13/2015
87/13/2015
97/13/2015
10
HOW ARE SGLT2 INHIBITORS DIFFERENT FROM OTHER ANTI-HYPERGLYCEMIC AGENTS?
• Non-insulin dependent mechanism
• SGLT2 inhibitors can be used in early or late type 2 diabetes
7/13/2015
11
FDA APPROVED SGLT2 INHIBITORS
Canagliflozin (INVOKANA)™ • Approved March 2013
Dapagliflozin (FARXIGA)™ • Approved in Europe since 2012 • FDA declined approval in 2012 due to possible cancer signal with drug • FDA recommends approval December 2013 • Approved January 2014
Empagliflozin ( Jardiance ) ™• Approved in January 2014
7/13/2015
12
CANAGLIFLOZIN (INVOKANA)™
• Reduces glucose absorption by 31% in first hour and 20% by next hour of food intake.
• Dosage:- : Initial: 100 mg once daily prior to first meal of the day; may increase to 300 mg once daily (only in patients with GFR ≥60 mL/minute/1.73 m2)
• Drug interactions :- UGT inducers (e.g., rifampin, phenytoin, phenobarbital, ritonavir) se metabolism of CFZ.
• C/I- renal impairement
7/13/2015
137/13/2015
147/13/2015
15
DAPAGLIFLOZIN (FARXIGA)
• Improves glycemic control in patients with T2DM when used as monotherapy, or when added to metformin, glimepiride or insulin.
• Helps in weight reduction
• Decrease in systolic blood pressure noted
• Less incidence of hypoglycemia
• Controversy- higher rate of bladder and breast cancer in the groups treated with dapagliflozin
7/13/2015
16
“An increased number of bladder cancers were diagnosed among Farxiga users in clinical trials so Farxiga is not recommended for patients with active bladder cancer. ”
7/13/2015
17
• Dose:- Initial: 5 mg once daily; may increase to 10 mg once daily.
• C/I:- renal impairement, bladder cancer
• Drug interactions:- may enhance hypoglycemic effects when used with insulin & sulfonylureas
7/13/2015
187/13/2015
197/13/2015
20
EMPAGLIFLOZIN ( JARDIANCE ) ™
• Pharmacokinetic studies of empagliflozin have shown that it is rapidly absorbed following oral administration, reaching maximal plasma concentrations within 1–3 hours.
• Once-daily administration of empagliflozin in patients with type 2 diabetes is well tolerated
• Dose :- Initial 10 mg once daily; may increase to 25 mg once daily
• No risk of hypoglycemia
7/13/2015
21
• C/I in renal impairement
• No hepatic impairement
• No drug interactions with CVS drugs like verapamil, ramipril, digoxin, and anticoagulant warfarin.
7/13/2015
227/13/2015
23
Advantages Vs. Disadvantages
7/13/2015
24
CONCLUSIONS
• SGLT2 inhibitors are a new option in treatment for type 2 diabetes
• Insulin independent mechanism of action allows use in early and late stages of diabetes
• Weight loss is a desirable side effect • Long term outcome studies are necessary to assess
risk of cardiovascular events
7/13/2015
257/13/2015